BenevolentBio

BenevolentAI is a clinical-stage biotechnology company that leverages a proprietary artificial intelligence platform to transform drug discovery and development. By integrating vast amounts of biomedical data with machine learning, the company identifies novel drug targets and develops small molecule candidates for complex diseases with high unmet needs. Its internal pipeline includes programs in immunology, inflammation, and oncology, with its lead candidate BEN-2293 having reached Phase 2 clinical trials for atopic dermatitis. Additionally, BenevolentAI has established significant strategic collaborations with major pharmaceutical companies, including AstraZeneca and Merck KGaA, to discover treatments for chronic kidney disease and pulmonary fibrosis. The company is headquartered in London and is listed on the Euronext Amsterdam stock exchange.